Download PDF
Thromb Haemost 2019; 119(01): 056-065
DOI: 10.1055/s-0038-1676345
Coagulation and Fibrinolysis
Georg Thieme Verlag KG Stuttgart · New York

Recombinant Human Soluble Thrombomodulin in Sepsis-Induced Coagulopathy: An Updated Systematic Review and Meta-Analysis

Kazuma Yamakawa
1   Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, Japan
,
Shuhei Murao
1   Division of Trauma and Surgical Critical Care, Osaka General Medical Center, Osaka, Japan
,
Morio Aihara
2   Department of Gastroenterology and Hematology, Hirosaki University Graduate School of Medicine, Hirosaki University, Hirosaki, Japan
› Author Affiliations
Further Information

Publication History

31 August 2018

16 October 2018

Publication Date:
31 December 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background Clinical effectiveness of recombinant human soluble thrombomodulin (rhTM) in sepsis or sepsis-induced coagulopathy remains a matter of dispute. Recently, the Sepsis Coagulopathy Asahi Recombinant LE Thrombomodulin (SCARLET) trial, the latest multinational multi-centre phase III randomized controlled trial, was completed.

Objective This article assesses the benefits and harms of rhTM therapy in sepsis-induced coagulopathy by updating our previous systematic review.

Methods We performed a systematic review and meta-analysis of rhTM therapy for sepsis-induced coagulopathy in randomized controlled trials. All-cause 28-day mortality as efficacy and serious bleeding complications as the adverse effect were measured as primary outcomes. We assessed the certainty of a body of evidence at the outcome level using the Grading of Recommendations Assessment, Development and Evaluation approach.

Results We analysed five trials enrolling 1,762 patients. Approximately 13% reduction in the risk of mortality was observed in the rhTM group, but the difference was not significant (relative risk, 0.87; 95% confidence interval, 0.74–1.03; p = 0.10; I 2 = 0%). Risk of serious bleeding complications did not increase with rhTM administration. We judged the certainty of evidence as moderate for mortality and low for serious bleeding. Trial sequential analysis indicated that only 42.0% of the required information size is actually available at this stage to reject or accept low risk-of-bias trials examining the anticipated effect for all-cause mortality.

Conclusion Even in this updated review including the latest SCARLET trial, we currently cannot make any declarative judgments about the beneficial effects of rhTM in sepsis-induced coagulopathy, although some favourable effects were suggested.

Keywords

anticoagulants - coagulopathy - critically ill - disseminated intravascular coagulation - septic shock

Supplementary Material

 

  • References

  • 1 Ferrer R, Artigas A, Levy MM. , et al; Edusepsis Study Group. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008; 299 (19) 2294-2303
    CrossrefPubMedGoogle Scholar
  • 2 Levy MM, Dellinger RP, Townsend SR. , et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36 (02) 222-231
    CrossrefPubMedGoogle Scholar
  • 3 Miller III RR, Dong L, Nelson NC. , et al; Intermountain Healthcare Intensive Medicine Clinical Program. Multicenter implementation of a severe sepsis and septic shock treatment bundle. Am J Respir Crit Care Med 2013; 188 (01) 77-82
    CrossrefPubMedGoogle Scholar
  • 4 Rhodes A, Evans LE, Alhazzani W. , et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45 (03) 486-552
    CrossrefPubMedGoogle Scholar
  • 5 Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011; 9 (Suppl. 01) 168-173
    CrossrefPubMedGoogle Scholar
  • 6 Levi M, Van Der Poll T. Thrombomodulin in sepsis. Minerva Anestesiol 2013; 79 (03) 294-298
    PubMedGoogle Scholar
  • 7 Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost 2003; 1 (07) 1515-1524
    CrossrefPubMedGoogle Scholar
  • 8 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235 (4794): 1348-1352
    CrossrefPubMedGoogle Scholar
  • 9 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264 (09) 4743-4746
    CrossrefPubMedGoogle Scholar
  • 10 Okamoto T, Tanigami H, Suzuki K, Shimaoka M. Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis. Crit Care Res Pract 2012; 2012: 614545
    PubMedGoogle Scholar
  • 11 Nakahara M, Ito T, Kawahara K. , et al. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS One 2013; 8 (09) e75961
    CrossrefPubMedGoogle Scholar
  • 12 Ito T, Kawahara K, Nakamura T. , et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 2007; 5 (01) 109-116
    CrossrefPubMedGoogle Scholar
  • 13 Abeyama K, Stern DM, Ito Y. , et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115 (05) 1267-1274
    CrossrefPubMedGoogle Scholar
  • 14 Li YH, Kuo CH, Shi GY, Wu HL. The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci 2012; 19: 34
    CrossrefPubMedGoogle Scholar
  • 15 Mohri M, Gonda Y, Oka M. , et al. The antithrombotic effects of recombinant human soluble thrombomodulin (rhsTM) on tissue factor-induced disseminated intravascular coagulation in crab-eating monkeys (Macaca fascicularis). Blood Coagul Fibrinolysis 1997; 8 (05) 274-283
    CrossrefPubMedGoogle Scholar
  • 16 Tanaka K, Tawara S, Tsuruta K, Hoppensteadt D, Fareed J. Pharmacological differentiation of thrombomodulin alfa and activated protein C on coagulation and fibrinolysis in vitro. Clin Appl Thromb Hemost 2018; 24 (06) 859-866
    CrossrefPubMedGoogle Scholar
  • 17 Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost 2015; 13 (04) 508-519
    CrossrefPubMedGoogle Scholar
  • 18 Asahi Kasei Pharma America Corporation. Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy. Available at: https://clinicaltrials.gov/ct2/show/NCT01598831?cond=ART-123&rank=5 . Accessed August 2, 2018
    PubMedGoogle Scholar
  • 19 Asahi Kasei Pharma Corporation. Preliminary results of overseas Phase III clinical study for ART-123; 2018. Available at: https://www.asahi-kasei.co.jp/asahi/en/news/2018/e180802.html . Accessed August 2, 2018
    PubMed
  • 20 Moher D, Liberati A, Tetzlaff J, Altman DG. ; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol 2009; 62 (10) 1006-1012
    CrossrefPubMedGoogle Scholar
  • 21 Liberati A, Altman DG, Tetzlaff J. , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62 (10) e1-e34
    CrossrefPubMedGoogle Scholar
  • 22 Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev 2016; 5 (01) 210
    CrossrefPubMedGoogle Scholar
  • 23 Aihara M. GRADE system for clinical practice guideline. 2nd ed. Hirosaki: Toppan Media; 2015
    PubMed
  • 24 Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. Updated Oc. Available at: www.guidelinedevelopment.org/handbook . Accessed November 18, 2018
    PubMedGoogle Scholar
  • 25 Hayakawa M, Saito S, Uchino S. , et al. Characteristics, treatments, and outcomes of severe sepsis of 3195 ICU-treated adult patients throughout Japan during 2011-2013. J Intensive Care 2016; 4: 44
    CrossrefPubMedGoogle Scholar
  • 26 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21 (11) 1539-1558
    CrossrefPubMedGoogle Scholar
  • 27 Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61 (01) 64-75
    CrossrefPubMedGoogle Scholar
  • 28 Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. J Clin Epidemiol 2008; 61 (08) 763-769
    CrossrefPubMedGoogle Scholar
  • 29 Aikawa N, Shimazaki S, Yamamoto Y. , et al. Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 2011; 35 (04) 349-354
    CrossrefPubMedGoogle Scholar
  • 30 Ushizawa H, Isotani E, Takahashi H, Sera T, Otomo Y. Randomized controlled trial of novel recombinant human soluble thrombomodulin (RTM) for sepsis with disseminated intravascular coagulation patients in Japan. Intensive Care Med 2012; 38 (01) S293-S294
    PubMedGoogle Scholar
  • 31 Vincent JL, Ramesh MK, Ernest D. , et al. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41 (09) 2069-2079
    CrossrefPubMedGoogle Scholar
  • 32 Hagiwara A, Tanaka N, Uemura T, Matsuda W, Kimura A. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial. BMJ Open 2016; 6 (12) e012850
    CrossrefPubMedGoogle Scholar
  • 33 Takahashi H, Isotani E, Ushizawa H. , et al. Effect of recombinant thrombomodulin for sepsis-induced disseminated intravascular coagulation. ICU&CCU 2011; 35: 581-584
    PubMedGoogle Scholar
  • 34 Asahi Kasei Pharma America Corporation. The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy (Scarlet2). Available at: https://clinicaltrials.gov/ct2/show/NCT03517501?cond=ART-123&rank=3 . Accessed August 2, 2018
    PubMedGoogle Scholar
  • 35 Umemura Y, Yamakawa K. Optimal patient selection for anticoagulant therapy in sepsis: an evidence-based proposal from Japan. J Thromb Haemost 2018; 16 (03) 462-464
    CrossrefPubMedGoogle Scholar
  • 36 Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. J Thromb Haemost 2016; 14 (03) 518-530
    CrossrefPubMedGoogle Scholar
  • 37 Zhang C, Wang H, Yang H, Tong Z. Recombinant human soluble thrombomodulin and short-term mortality of infection patients with DIC: a meta-analysis. Am J Emerg Med 2016; 34 (09) 1876-1882
    CrossrefPubMedGoogle Scholar